Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A new Revision: v3.4.3 entry was added to the history, and the previous Revision: v3.4.2 entry was removed.
    Difference
    0.1%
    Check dated 2026-03-11T16:51:36.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    A new Revision: v3.4.2 has been added, and earlier entries including a government-funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2026-02-11T01:52:50.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added an administrative notice about potential processing delays due to a lapse in government funding. Version updated from v3.4.0 to v3.4.1.
    Difference
    0.6%
    Check dated 2026-02-03T22:14:43.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Glossary visibility has been added, and the history view now uses green and red highlights to show additions and deletions, with an updated revision label (Revision: v3.4.0).
    Difference
    0.8%
    Check dated 2026-01-27T20:03:23.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    A new revision entry v3.3.4 has been added to the history, and v3.3.3 has been removed. This keeps the historical record of the study's documentation up to date.
    Difference
    0.1%
    Check dated 2026-01-20T14:44:22.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A new 'Revision: v3.3.3' label appears on the page, while the 'HHS Vulnerability Disclosure' and the 'Revision: v3.3.2' entries are removed from the footer.
    Difference
    0.2%
    Check dated 2025-12-22T21:48:24.000Z thumbnail image

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.